ATILA BIOSYSTEMS, INC.

Medtech · Private

AmpFire® HPV Genotyping test using loop-mediated isothermal amplification (LAMP) for rapid, low-cost detection and risk stratification of high-risk HPV types

Grants
$2.0M
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
7
1 granted · 6 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · PROGRESS: PRevention of cervical cancer using the Genotyping scREening and Same-day Self-sampling$1,011,310
Federal grantDepartment of Health and Human Services · Phase II · PROGRESS: PRevention of cervical cancer using the Genotyping scREening and Same-day Self-sampling$986,359
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1979Bioliberty Ltd—$2.9M
1980TRICORDER ARRAY TECHNOLOGIES, LLC——
1981PROLUNG INC—$2.8M
1982ATILA BIOSYSTEMS, INC.——
1983Spine Align LLC——
1984VERSAGO VASCULAR ACCESS, INC.—$440K
1985TRANSONIC SYSTEMS, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 1 granted of 7
  • Omega Amplificationapplication
  • Omega Amplificationgranted
  • Amplification With Primers Of Limited Nucleotide Compositionapplication
  • Omega Amplificationapplication
  • Omega Amplificationapplication
  • Amplification With Primers Of Limited Nucleotide Compositionapplication
  • Amplification With Primers Of Limited Nucleotide Compositionapplication

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.